Rentosertib's biological aging signal in Insilico's trial

Rentosertib, an AI-designed drug developed by Insilico Medicine to treat idiopathic pulmonary fibrosis, moved all six proteomic aging clock measurements in a favorable direction in clinical trial data. Researchers reanalyzing blood samples from the lung disease trial found that patients taking the drug consistently showed lower estimated biological ages across six independent clocks. The strongest effects appeared around week four, with some doses averaging 3 to 4 years younger biologically. The dose that performed best on biological aging was not the same dose that performed best on lung function. Nobel laureate Michael Levitt argued that agreement across six independent clocks may carry more weight than any single measurement, because the clocks use different features and training data. Researchers caution that the analysis cannot prove the drug actually slowed aging itself. Insilico founder Alex Zhavoronkov called it "the most important paper in my life to date."